

=====
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) October 27, 2005

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

MASSACHUSETTS 1-10730 04-2882273
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
400 Wood Road 02184
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

- [] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On October 27, 2005 Haemonetics Corporation (the "Company") issued a press
release announcing financial results for the second quarter and six months ended
October 1, 2005. A copy of the release is furnished with this report as exhibit
99.1.

The information in this current report on Form 8-K and the exhibit attached
hereto shall not be deemed "filed" for the purposes of Section 18 of the
Securities and Exchange Act of 1934 (the "Exchange Act") or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act,
regardless of any general incorporation language in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

99.1: Press Release of Haemonetics Corporation dated October 27, 2005 announcing
financial results for the second quarter and six months ended October 1, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

(Registrant)

Date: October 27, 2005

/s/ RONALD J. RYAN

Ronald J. Ryan, Vice President
and Chief Financial Officer

99.1 Press Release issued by Haemonetics Corporation on October 27, 2005.

HAEMONETICS REPORTS SECOND QUARTER FISCAL YEAR 2006 EARNINGS AND RAISES FULL YEAR EARNINGS PER SHARE GUIDANCE FOLLOWING ARBITRATION AWARD

BRAINTREE, Mass., Oct. 27 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) reported today second quarter fiscal year 2006 net revenue of \$100.5 million, a 10.5% increase over the second quarter of fiscal year 2005 and year-to-date revenue of \$204 million, a 9.8% increase over FY05. Diluted net earnings per share for the quarter were \$0.40, up 17.6% over Q2:05 and for year-to-date are \$0.87, up 19.2% over FY05.

Brad Nutter, Haemonetics' President and CEO, said, "I am pleased with the performance we posted in the quarter with results coming from strength in sales in plasma and red cell disposables, equipment, and information management. Moreover, the quarter was also marked with a substantial investment in new products."

The Company also reaffirmed its annual guidance of revenue growth of 11-13%, operating income growth of approximately 20%, and operating margin exceeding 16%, and announced it was raising its annual earnings per share guidance. As a result of winning a previously disclosed arbitration proceeding, Haemonetics received \$31 million in October. The Company had previously guided that diluted net earnings per share for the year would be in the range of \$1.73 to \$1.83. The receipt of the cash will add approximately \$0.61 to Haemonetics' earnings per share for the year. Therefore, the Company is raising its annual diluted GAAP net earnings per share estimates to a range of \$2.34 to \$2.44.

The arbitration award will also result in approximately \$28 million in pre-tax income in Q3:06. The majority of the award will be recorded as other income, and Haemonetics anticipates a related tax expense of about \$11 million. The award will increase Haemonetics' Q3:06 cash balance by approximately \$20 million.

FINANCIAL HIGHLIGHTS

Haemonetics reported the following additional financial results:

- * Q2:06 gross profit of \$52 million, up 13.6% from \$46 million in Q2:05; year-to-date gross profit of \$106 million, up 14.7% from \$93 million in FY05
- * Q2:06 gross margin of 51.5%, up 140 basis points from Q2:05; year-to-date gross margin of 52.2%, up 230 basis points from FY05
- * Q2:06 operating expenses of \$36 million, up 15.0% from \$32 million in Q2:05; year-to-date operating expenses of \$72 million, up 13.5% from \$64 million in FY05
- * Q2:06 operating income of \$15 million, up 10.6% from \$14 million in Q2:05; year-to-date operating income of \$34 million, up 17.3% from \$29 million in FY05
- * Q2:06 operating margin of 15.3%, level with Q2:05; year-to-date operating margin of 16.6%, up 100 basis points from FY05

In the quarter, net income was negatively affected by a \$1.1 million reserve for equipment and components for an older product no longer expected to be marketed. However, this was offset by favorable currency exchange, higher short-term interest rates, and a lower tax rate. The lower tax rate (33.3% in Q2:06 versus 35.3% in Q2:05) is a result of a favorable determination of a tax deduction.

Haemonetics achieved an increase in cash and short term investments on the balance sheet of \$11.9 million over Q1:06 for a second quarter end cash balance of \$210 million. The Company also generated \$14.3 million in cash flow from operating activities for the quarter.

Haemonetics will post detailed information on the positive effects of currency and the Company's annual guidance on the web at http://www.haemonetics.com/site/content/investor/fin_history.asp.

DONOR PRODUCT LINE HIGHLIGHTS

Plasma disposables revenue was \$26 million for the quarter, up 7.0% from Q2:05 and \$53 million year-to-date, up 7.1% from FY05. In the quarter, sales benefited from disposables unit growth in the U.S. as the plasma collection market rebounds and as Haemonetics gains new customers.

Blood bank revenue was \$32 million for the quarter, down 3.4% over Q2:05 and \$65 million year-to-date, up 1.2% from FY05. In Q2 of last fiscal year, the Company had a large, opportunistic sale of an intravenous solution that did not recur in Q2 of this fiscal year.

Red cell disposables revenue was \$9 million for the quarter, up 33.8% over Q2:05 and \$17 million year-to-date, up 32.4% from FY05. The majority of the quarterly revenue growth came from the U.S. where sales increased 47% over Q2:05. Unit growth and an increase in sales of Haemonetics' higher-priced filtered disposable set were key drivers of U.S. red cell disposables revenue.

PATIENT PRODUCT LINE HIGHLIGHTS

Disposables revenue for the Patient family of products was \$20 million for the quarter, level with Q2:05 and \$43 million year-to-date, up 4.4% from FY05. OrthoPAT(R) brand disposables revenue was \$4.5 million for the quarter, up 2.6% over Q2:05 and \$10 million year-to-date, up 15.3% from FY05. As expected, U.S. OrthoPAT sales declined sequentially from Q1:06 as the Company shifted U.S. sales from a distribution relationship to direct sales on August 29, 2005.

OTHER REVENUES

Particularly strong equipment and miscellaneous/service revenue growth in the second quarter contributed to the Company's overall revenue growth. Q2:06 equipment sales were \$7 million, up 156.7% over Q2:05. Equipment growth came from the sales of cell processing systems in the U.S., plasma systems in Europe and the newly introduced CS5+ devices worldwide. Miscellaneous and service revenue grew to \$7 million in Q2:06, up 69.6% over Q2:05. Most of this revenue growth came from the 5D Information Management division as it made gains in penetrating the broader blood collection market for its information technology systems.

OTHER ANNOUNCEMENTS

Haemonetics announced today that it has amended its development agreement with Arrayx, Inc. to expand the field of use for research and product development. The new agreement gives Haemonetics exclusive rights to applications, using Arrayx's nanotechnology, beyond blood to all of human healthcare.

The Company also said that it has received FDA 510(k) clearance of its SmartSuction(R) HARMONY(TM) surgical suction system. The Company has begun customer acceptance trials of this device as part of its planned product launch.

CONFERENCE CALL

Haemonetics will hold a conference call on Thursday, October 27th at 10:00 am eastern to review the financial and operational performance of the quarter.

Interested parties can participate by calling (800) 322-0079 (US only) or (973) 935-2100. The call will be replayed through November 11th at (877) 519-4471 (US only) or (973) 341-3080 using PIN 6507162.

INVESTOR CONFERENCE

Brad Nutter will be presenting at the Piper Jaffray Conference in Chicago on December 8, 2005.

Haemonetics (NYSE: HAE) is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. To learn more about Haemonetics' products and markets, visit its web site at <http://www.haemonetics.com>.

This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.

CONTACT:

Julie Fallon

Tel. (781) 356-9517

Alternate Tel. (617) 320-2401

fallon@haemonetics.com

HAEMONETICS CORPORATION FINANCIAL SUMMARY
(UNAUDITED DATA IN THOUSANDS, EXCEPT PER SHARE DATA)

CONSOLIDATED STATEMENTS OF INCOME
SECOND QUARTER FYE06

	10/01/05	10/02/04	%
	-----	-----	-----
			Inc/ (Dec) vs prior year

NET REVENUES	\$ 100,488	\$ 90,923	10.5
Gross profit	51,765	45,549	13.6
R&D	6,283	4,253	47.7
S, G & A	30,103	27,385	9.9
Operating expenses	36,386	31,638	15.0
Operating income	15,379	13,911	10.6
Interest expense	(522)	(636)	(17.9)
Interest income	1,083	502	115.7
Other income/(expense), net	481	(69)	(797.1)
Income before taxes	16,421	13,708	19.8
Tax expense	5,476	4,834	13.3
NET INCOME	\$ 10,945	\$ 8,874	23.3
Net income per common share assuming dilution	\$ 0.40	\$ 0.34	17.6
Weighted average number of shares			
Basic	26,395	25,258	
Diluted	27,354	25,784	
			Inc/ (Dec) vs prior year profit margin %

PROFIT MARGINS			
Gross profit	51.5%	50.1%	1.4
R&D	6.3%	4.7%	
S, G & A	30.0%	30.1%	
Operating income	15.3%	15.3%	
Income before taxes	16.3%	15.1%	1.2
Net income	10.9%	9.8%	

CONSOLIDATED STATEMENTS OF INCOME YEAR-TO-DATE FOR FYE06

	10/01/05	10/02/04	% Inc/(Dec) vs prior year
	-----	-----	-----
NET REVENUES	\$ 203,661	\$ 185,525	9.8
Gross profit	106,289	92,649	14.7
R&D	11,824	8,307	42.3
S, G & A	60,591	55,469	9.2
Operating expenses	72,415	63,776	13.5
Operating income	33,874	28,873	17.3
Interest expense	(1,063)	(1,297)	(18.0)
Interest income	2,396	865	177.0
Other income/(expense), net	1,345	(301)	(546.8)
Income before taxes	36,552	28,140	29.9
Tax expense	12,723	9,446	34.7
NET INCOME	\$ 23,829	\$ 18,694	27.5
Net income per common share assuming dilution	\$ 0.87	\$ 0.73	19.2
Weighted average number of shares			
Basic	26,338	25,207	
Diluted	27,279	25,681	
			Inc/(Dec) vs prior year profit margin %

PROFIT MARGINS			
Gross profit	52.2%	49.9%	2.3
R&D	5.8%	4.5%	
S,G&A	29.8%	29.9%	
Operating income	16.6%	15.6%	1.0
Income before taxes	17.9%	15.2%	2.7
Net income	11.7%	10.1%	

REVENUE ANALYSIS

SECOND QUARTER

	10/01/05	10/02/04	% Inc/ (Dec)
Revenues by Geography			
United States	\$ 37,930	\$ 30,403	24.8
International	62,558	60,520	3.4
Net Revenues	\$ 100,488	\$ 90,923	10.5
Disposable Revenues by Product Family			
Donor:			
Plasma	\$ 25,938	\$ 24,238	7.0
Blood Bank	32,193	33,338	(3.4)
Red Cell	8,903	6,653	33.8
	\$ 67,034	\$ 64,229	4.4
Patient:			
Surgical	\$ 19,930	\$ 20,045	(0.6)
Subtotal	\$ 86,964	\$ 84,274	3.2
Equipment	\$ 6,623	\$ 2,580	156.7
Misc & Service	6,901	4,069	69.6
Net Revenues	\$ 100,488	\$ 90,923	10.5

SIX MONTHS ENDED

	10/01/05	10/02/04	% Inc/ (Dec)
Revenues by Geography			
United States	\$ 76,153	\$ 63,310	20.3
International	127,508	122,215	4.3
Net Revenues	\$ 203,661	\$ 185,525	9.8
Disposable Revenues by Product Family			
Donor:			
Plasma	\$ 53,241	49,724	7.1
Blood Bank	64,883	64,107	1.2
Red Cell	17,358	13,114	32.4
	135,482	126,945	6.7
Patient:			
Surgical	\$ 42,615	\$ 40,818	4.4
Subtotal	\$ 178,097	\$ 167,763	6.2
Equipment	12,734	9,253	37.6
Misc & Service	12,830	8,509	50.8
Net Revenues	\$ 203,661	\$ 185,525	9.8

CONSOLIDATED BALANCE SHEETS

	Period ending	
	10/01/05	4/02/05
ASSETS		
Cash & cash equivalents	\$ 209,981	\$ 185,815
Accounts receivable, net	83,409	80,719
Inventories, net	57,581	53,088
Other current assets	28,089	23,989
Total current assets	379,060	343,611
Net PP&E	67,075	69,337
Other assets	53,088	54,809
Total assets	\$ 499,223	\$ 467,757

	Period ending	
	10/01/05	4/02/05
LIABILITIES & STOCKHOLDERS' EQUITY		
S/T debt & current maturities	\$ 27,643	\$ 26,612
Other current liabilities	60,256	61,310
Total current liabilities	87,899	87,922
Long-term debt	18,967	19,231
Other long-term liabilities	5,107	5,469
Stockholders' equity	387,250	355,135
Total liabilities & equity	\$ 499,223	\$ 467,757